Skip to main content
Top
Published in: Irish Journal of Medical Science (1971 -) 4/2013

01-12-2013 | Original Article

Hereditary metabolic diseases (HMDs) in adult practice in Ireland: a preliminary assessment

Authors: L. Morrissey, C. A. Tiernan, D. Lambert, E. O’Reilly, E. P. Treacy

Published in: Irish Journal of Medical Science (1971 -) | Issue 4/2013

Login to get access

Abstract

Background

Hereditary metabolic diseases (HMDs) are almost all rare diseases, many of which, if ascertained are treatable and preventable causes of intellectual and general disability. The improved detection and treatment of HMDs in paediatric practice has resulted in increased survival into adult life. The identification of adult patients with HMDs who may benefit from new emerging treatments is challenging. As for many rare diseases, there are difficulties tracing patients for many of these conditions in current Irish coding systems and lack of established patient Registries.

Methods

In this study, we describe the efforts made to trace Irish adult patients with potentially treatable HMDs using (1) a mailed questionnaire sent to all currently registered adult Medical Specialists practising in Ireland requesting details of all cases seen over the 4-year period 2007–2010, (2) the analysis of HIPE in-patient data during this time and (3) analysis of the database held at NCIMD.

Conclusions

The current systems in place for identification and coding of potentially treatable HMDs are very deficient. This emphasizes the need to prioritize the development of a National HMD Registry.
Literature
1.
go back to reference Jimenez-Sanchez G, Childs B, Valle D (2008) Chapter 4. The effect of Mendelian disease on human health. In: Vallc D, Boaudet A, Vogelstein B et al (eds) OMMBID the metabolic and molecular bases of inherited disease. McGraw-Hill, New York. http://www.MMBIDOnline.com Jimenez-Sanchez G, Childs B, Valle D (2008) Chapter 4. The effect of Mendelian disease on human health. In: Vallc D, Boaudet A, Vogelstein B et al (eds) OMMBID the metabolic and molecular bases of inherited disease. McGraw-Hill, New York. http://​www.​MMBIDOnline.​com
2.
go back to reference Naughten ER, Kiely B, Saul I, Murphy D (1987) Phenylketonuria: outcome and problems in a ‘diet-for-life’ clinic. Eur J Pediatr 146(Suppl 1):A23–A24PubMedCrossRef Naughten ER, Kiely B, Saul I, Murphy D (1987) Phenylketonuria: outcome and problems in a ‘diet-for-life’ clinic. Eur J Pediatr 146(Suppl 1):A23–A24PubMedCrossRef
3.
go back to reference Geelhoed EA, Lewis B, Hounsome D, O’Leary P (2005) Economic evaluation of neonatal screening for phenylketonuria and congenital hypothyroidism. J Paediatr Child Health 41(11):575–579PubMedCrossRef Geelhoed EA, Lewis B, Hounsome D, O’Leary P (2005) Economic evaluation of neonatal screening for phenylketonuria and congenital hypothyroidism. J Paediatr Child Health 41(11):575–579PubMedCrossRef
4.
go back to reference Treacy EP (2008) Update, chapter 5, the treatment of genetic disease. In: Vallc D, Boaudet A, Vogelstein B et al (eds) OMMBID the metabolic and molecular bases of inherited disease. McGraw-Hill, New York. http://www.MMBIDOnline.com Treacy EP (2008) Update, chapter 5, the treatment of genetic disease. In: Vallc D, Boaudet A, Vogelstein B et al (eds) OMMBID the metabolic and molecular bases of inherited disease. McGraw-Hill, New York. http://​www.​MMBIDOnline.​com
5.
6.
go back to reference Karnebeek CDM, Stockler S (2012) Treatable inborn errors of metabolism causing intellectual disability: a systematic literature review. Mol Genet Metab 105(3):368–381PubMedCrossRef Karnebeek CDM, Stockler S (2012) Treatable inborn errors of metabolism causing intellectual disability: a systematic literature review. Mol Genet Metab 105(3):368–381PubMedCrossRef
7.
9.
go back to reference Coss KP, Doran PP, Owoeye C et al (2013) Classical galactosaemia in Ireland: incidence, complications and outcomes of treatment. J Inherit Metab Dis 26(1):21–27CrossRef Coss KP, Doran PP, Owoeye C et al (2013) Classical galactosaemia in Ireland: incidence, complications and outcomes of treatment. J Inherit Metab Dis 26(1):21–27CrossRef
11.
go back to reference Rath A, Olry A, Dhombres F, Brandt MM, Urbero B, Ayme S (2012) Representation of rare diseases in health information systems: the Orphanet approach to serve a wide range of end users. Hum Mutat 33(5):803–808PubMedCrossRef Rath A, Olry A, Dhombres F, Brandt MM, Urbero B, Ayme S (2012) Representation of rare diseases in health information systems: the Orphanet approach to serve a wide range of end users. Hum Mutat 33(5):803–808PubMedCrossRef
13.
go back to reference Del Toro-Riera M (2007) Follow-up of patients with Hunter syndrome: the Hunter Outcome Survey (HOS) registry. Rev Neurol 19(44 Suppl 1):S13–S17 Del Toro-Riera M (2007) Follow-up of patients with Hunter syndrome: the Hunter Outcome Survey (HOS) registry. Rev Neurol 19(44 Suppl 1):S13–S17
Metadata
Title
Hereditary metabolic diseases (HMDs) in adult practice in Ireland: a preliminary assessment
Authors
L. Morrissey
C. A. Tiernan
D. Lambert
E. O’Reilly
E. P. Treacy
Publication date
01-12-2013
Publisher
Springer London
Published in
Irish Journal of Medical Science (1971 -) / Issue 4/2013
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-013-0927-9

Other articles of this Issue 4/2013

Irish Journal of Medical Science (1971 -) 4/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine